MaryjoJLechowiczMD

Hematology • Atlanta, GA

Hematologic Oncology

Professor, Hematology and Medical Oncology, Emory University School of Medicine

Join to view full profile

Dr. Lechowicz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lechowicz's full profile

Already have an account?

Office
1365 Clifton Rd Ne
Atlanta, GA 30322
Phone+1 404-778-1900
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1996 - 2000
SUNY Upstate Medical UniversityClass of 1996

Certifications & Licensure

GA State Medical License 2003 - 2025
MD State Medical License 2000 - 2004
American Board of Internal Medicine Medical Oncology

Clinical Trials

Valproic Acid in Treating Patients With Kaposi's Sarcoma Start of enrollment: 2005 Feb 01
Completed
Not Applicable
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma Start of enrollment: 2011 Jun 21
Completed
Phase 1
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma Start of enrollment: 2013 Mar 07
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.
Christy Smith, Robert Ristuccia, Karen Dwyer, Mary Jo Lechowicz> ;International Journal of Hematology. 2024 Mar 27
Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
Mateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, Adam Bagg, Joshua D Brandstadter, Gordan Srkalovic, Natalie Mango, Daisy Alapat, Mary Jo Lechowicz, Hongzhe Li, ...> ;Haematologica. 2024 Jan 11
Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature.
Joshua D Preston, Caroline S Jansen, Siddhartha Kosaraju, Tim Niyogusaba, Tony Z Zhuang, Sally W Iwamoto, Spencer K Hutto, Mary Jo Lechowicz, Pamela B Allen> ;CNS Oncology. 2023 Dec 1
2 citations
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Sheila K Pierson, Megan S Lim, Gordan Srkalovic, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Natalie Mango, Criswell Lavery, Bridget Austin, Daisy Alapat, Mary...> ;Blood Advances. 2023 Nov 14
Ongoing symptoms following complete surgical excision in unicentric Castleman disease.
Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Freda R Coren, Adam Bagg, Gordan Srkalovic, Daisy Alapat, Frits van Rhee, Megan S Lim, Mary Jo Lechowicz, Sheila K ...> ;American Journal of Hematology. 2023 Nov 1
2 citations
Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study.
Tony Zibo Zhuang, Ashley McCook-Veal, Jeffrey Switchenko, Erica S Tarabadkar, Katelin Baird, Colin O'Leary, Darina Paulino, Mary Jo Lechowicz, Pamela B Allen, Tim Niyo...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
4 citations
Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
Pamela B Allen, Ashley A McCook-Veal, Jeffrey M Switchenko, Darina M Paulino, Katelin M Baird, Erica S Tarabadkar, Mary Jo Lechowicz, Niyogusaba, T.> ;Cancer. 2023 Feb 15
3 citations
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
Chang, A., Akhtar, A., Lai, L., Orellana-Noia, V., Linderman, S., McCook-Veal, A., Switchenko, J., Saini, M., Valanparambil, R., Blum, K., Allen, P., Lechowicz, M., Ro...> ;Cancer Research Communications. 2022 Dec 1
2 citations
Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome.
Pamela B Allen, Subir Goyal, Colin O'Leary, Amy Ayers, Erica S Tarabadkar, Mohammad K Khan, Mary Jo Lechowicz, Niyogusaba, T.> ;JAMA Dermatology. 2022 Nov 1
1 citations
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
David C Fajgenbaum, Sheila K Pierson, Karan Kanhai, Adam Bagg, Daisy Alapat, Megan S Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S Uldrick, Frits van Rhee> ;British Journal of Haematology. 2022 Jul 1
2 citations
Mitigation strategies among cutaneous T-cell lymphoma patients with positiveskin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia.
Pamela B Allen, Subir Goyal, Jeffrey Switchenko, Erica Tarabadkar, Stephanie Pouch, Priya Parikh, Alex Palmer, Dylan Martini, Esther Kim, Mary Jo Lechowicz> ;Leukemia & Lymphoma. 2023 Mar 1
2 citations
African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center.
Dylan J Martini, Subir Goyal, Jeffrey M Switchenko, Mary Jo Lechowicz, Pamela B Allen> ;Leukemia & Lymphoma. 2022 Sep 1
45 citations
Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.
Elise A. Olsen, Sean Whittaker, Rein Willemze, Lauren C. Pinter-Brown, Francine M. Foss, Larisa J. Geskin, Lawrence H. Schwartz, Steven M. Horwitz, Joan Guitart, John ...> ;Blood. 2021 Nov 10
1 citations
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.
Mridula Krishnan, R. Gregory Bociek, Michelle A. Fanale, Swaminathan P. Iyer, Mary Jo Lechowicz, Philip J. Bierman, James O. Armitage, Matthew A. Lunning, Avyakta Kall...> ;Annals of Hematology. 2021 Oct 20
1 citations
Racial differences in clinical presentation and outcomes in mycosis fungoides and Sézary syndrome in the United States: a large singe center retrospective analysis.
Pamela B. Allen, Subir Goyal, Colin Burke O'Leary, Amy A. Ayers, Mohammad K. Khan, Mary Jo Lechowicz> ;European Journal of Cancer. 2021 Oct 1
6 citations
T-Cell Receptor Gene Rearrangement Clonality, Flow Cytometry Status, and Associated Outcomes in Early-Stage Cutaneous T-Cell Lymphoma.
Jennifer A. Marks, Jeffrey M. Switchenko, Dylan J. Martini, Erica Shantha Tarabadkar, Mohammad K. Khan, Mary Jo Lechowicz, Pamela B. Allen> ;JAMA Dermatology. 2021 Aug 1
3 citations
Nivolumab-associated cutaneous T-cell lymphoma.
Jennifer A. Marks, Douglas C. Parker, L. Crain Garrot, Mary Jo Lechowicz> ;JAAD Case Reports. 2021 Jan 10
69 citations
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
Frits van Rhee, Eric Oksenhendler, Gordan Srkalovic, Peter M. Voorhees, Megan S. Lim, Angela Dispenzieri, Makoto Ide, Sophia A. T. Parente, Stephen Schey, Matthew Stre...> ;Blood Advances. 2020 Dec 8
5 citations
Maintenance Therapy for Cutaneous T-cell Lymphoma After Total Skin Electron Irradiation: Evidence for Improved Overall Survival With Ultraviolet Therapy.
Matthew R Kudelka, Jeffrey M. Switchenko, Mary Jo Lechowicz, Natia Esiashvili, Christopher R. Flowers, Mohammad K. Khan, Pamela B. Allen> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 1
16 citations
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
David C. Fajgenbaum, David Wu, Aaron M. Goodman, Raymond S.M. Wong, Amy Chadburn, Sunita D. Nasta, Gordan Srkalovic, Sudipto Mukherjee, Heather A. Leitch, Raj Jayantha...> ;American Journal of Hematology. 2020 Sep 25
42 citations
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Auris Huen, Bradley M. Haverkos, Jasmine Zain, Ramchandren Radhakrishnan, Mary Jo Lechowicz, Sumana Devata, Neil J. Korman, Lauren C. Pinter-Brown, Yasuhiro Oki, Praja...> ;Cancers. 2020 Aug 15
9 citations
Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).
Pamela B. Allen, Jeffrey M. Switchenko, Amy A. Ayers, E. S. Kim, Mary Jo Lechowicz> ;Leukemia & Lymphoma. 2020 Jun 19
2 citations
Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab.
Sarah Westergaard, Mary Jo Lechowicz, Maggie Harrington, Justin Elsey, Jack L. Arbiser, Mohammad K. Khan> ;JAAD Case Reports. 2020 Jun 4
13 citations
Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia
Lindsay C Clough, A. Rana Bayakly, Kevin C. Ward, Mohammad K. Khan, Suephy C. Chen, Mary Jo Lechowicz, Christopher R. Flowers, Pamela B. Allen, Jeffrey M. Switchenko> ;Cancer. 2020 Apr 15
7 citations
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
Jonathon B. Cohen, Lai Wei, Kami J. Maddocks, Beth Christian, Leonard T. Heffner, Amelia Langston, Mary Jo Lechowicz, Pierluigi Porcu, Christopher R. Flowers, Steven M...> ;Cancer. 2020 Mar 15
Join now to see all

Abstracts/Posters

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Mary Jo Lechowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Evaluation of Maintenance Therapy in Cutaneous T-Cell Lymphoma Patients Receiving Total Skin Electron Beam Radiation Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018